Processa Pharmaceuticals (PCSA) CFO adds 2,190 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted made an open-market purchase of the company’s Common Stock. On the reported date, he bought 2,190 shares at a price of $2.69 per share and, after this transaction, directly held a total of 6,498 shares.

Insider Trade Summary

Net Buyer: 2,190 shares ($5,891)

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 2,190 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,190	$2.69	$6K

Holdings After Transaction: Common Stock — 6,498 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 2,190 shares Purchase price: $2.69 per share Shares held after transaction: 6,498 shares

3 metrics

Shares purchased 2,190 shares Open-market purchase of Common Stock

Purchase price $2.69 per share Price paid in the reported transaction

Shares held after transaction 6,498 shares Direct ownership following the purchase

Key Terms

open-market purchase, Common Stock, Form 4

3 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		P		2,190	A	$2.69	6,498	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Processa Pharmaceuticals (PCSA) report?

Processa Pharmaceuticals reported that its Chief Financial Officer, Russell Skibsted, made an open-market purchase of Common Stock. He acquired 2,190 shares at $2.69 per share and increased his directly held position to 6,498 shares following the transaction.

Who is the insider involved in the latest PCSA Form 4 filing?

The insider is Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals. He filed a Form 4 reporting an open-market purchase of 2,190 shares of Common Stock at $2.69 per share, bringing his directly held total to 6,498 shares after the transaction.

How many Processa Pharmaceuticals (PCSA) shares did the CFO buy?

The CFO, Russell Skibsted, bought 2,190 shares of Processa Pharmaceuticals Common Stock. These shares were purchased in an open-market transaction at a price of $2.69 per share, resulting in direct ownership of 6,498 shares after the trade.

What price did PCSA’s CFO pay per share in the reported trade?

Processa Pharmaceuticals’ CFO paid $2.69 per share in the reported trade. He purchased 2,190 shares of Common Stock in an open-market transaction and, after completing this purchase, directly owned a total of 6,498 shares in the company.

How many Processa Pharmaceuticals (PCSA) shares does the CFO hold after this transaction?

After the transaction, CFO Russell Skibsted directly holds 6,498 shares of Processa Pharmaceuticals Common Stock. This reflects the addition of 2,190 shares purchased in an open-market transaction at $2.69 per share, as disclosed in the Form 4 filing.

Was the recent PCSA insider transaction a purchase or a sale?

The recent insider transaction for Processa Pharmaceuticals was a purchase. CFO Russell Skibsted executed an open-market buy of 2,190 Common Stock shares at $2.69 per share, increasing his directly held position to 6,498 shares following the transaction.